Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAP-X: Xolair in Rush Multi Oral Immunotherapy
NCT02643862Phase 2Completed
- Sponsor
- Stanford University
- Start
- Mar 2015
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in food allergy, sponsored by Stanford University. Started Mar 2015; status: completed.
02
Drugs
omalizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT02643862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643862.